The Week Ahead In Biotech: Conferences, PDUFA Dates And IPOs

Large-cap pharma stocks are seeing some upward momentum and are on track to f.....»»

Biotech stocks held steady in the recent week as earnings from the sector continue to trickle in. The week also saw presentations of clinical t.....»»

Biotech stocks advanced for a third straight week, defying the broader market weakness. The space got solid support from positive stock reactions to presentations made at hematology and breast cancer conferences. read more.....»»

Biotech news flow remained light last week, although there were some notable developments such as FDA panel reviews of opioid pain drugs, a few clinical data readouts, presentations and updates at the JPMorgan Healthcare conference. Here are the key c.....»»

Biotech news flow remained light last week, a.....»»

Biotech stocks are on track to extend their losses, bucking the positive broader market sentiment. The week saw Achaogen Inc (NASDAQ: AKAO) filing for Chapter 11 bankruptcy and negative clinical readouts .....»»

Biotech stocks witnessed a slowdown in momentum last week, which was a relatively slow one in terms of news flow. Amgen, Inc. read more.....»»

After a lackluster show mid-way through the week despite M&A news and earnings, the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) staged a recovery in the later part of the week. As the sector struggle.....»»

After a lackluster show mid-way through the week despite M&A news and earnings, the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) staged a recovery in the later part of the week. read more.....»»

The ASCO conference closed Tuesday, although presentations at the conference triggered some huge stocks moves. read more.....»»

A bit of a lull took place in the biotech space ahead of earnings season; IPO activity was non-existent, but there was some action on account of clinical trial results. Here's a look at the upcoming week's catalytic events. read more.....»»

A bit of a lull took place in the biotech space ahead of earnings season; IPO activity was non-existent, but there was some action on account of clinical trial results. He.....»»

After recording stellar gains of 4.3 percent in the week ended Aug. 31 to close the month .....»»

After recording stellar gains of 4.3 percent in the week ended Aug. 31 to close the month in the green, the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) saw a moderation in momentum in the holiday-shortened week ending Sept. 7. read more.....»»

As we step into the final quarter of 2018, biotech stocks have recorded double-digit gains for the year-to-date period. Will the run up continue? Stay tuned to the following events of the upcoming week. read more.....»»

Notwithstanding the scanty news flow, biotech stocks came under intense s.....»»

Notwithstanding the s.....»»

The earnings season hasn't panned out well for pharma companies, with Amgen, Inc. (NASDAQ: AMGN), Novartis AG (NYS.....»»

The earnings season hasn't panned out well for pharma companies, with Amgen, Inc. (NASDAQ: AMGN), Novartis AG (NYSE: NVS) and Illumina, Inc. read more.....»»

Biotech stocks reversed course in the week ended April 16, with the sector re.....»»